Dendreon Withdraws Previous FY2011 Revenue Guidance of $350-400M; Expects Modest QoQ Growth

by Eddie Staley, Benzinga Editor
August 3, 2011 4:41 PM | 14 seconds read |
Dendreon DNDN expects that adoption of the new reimbursement paradigm will take time. Accordingly, Dendreon is withdrawing its previous guidance of $350-400 million in revenue for 2011 and currently expects modest quarter over quarter revenue growth for the remainder of this year.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: EarningsNewsGuidanceBiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!